DarioHealth Reports Q4: Net Loss Up 32% Amid Revenue Shift
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy DRIO?
Source: seekingalpha
- Financial Performance Decline: DarioHealth's Q4 non-GAAP net loss increased by 32% to $6.5 million, reflecting the financial pressures faced during the company's transition.
- Significant Revenue Drop: The company reported revenue of $5.2 million, a 31.6% year-over-year decline, although it beat expectations by $0.15 million, primarily due to the shift from one-time revenues to annual recurring revenues (ARR).
- Client Relationship Changes: A significant scope change with a large national health plan client resulted in revenue decline, as this client was not renewed at the beginning of 2025, highlighting challenges in client retention for DarioHealth.
- Strategic Transition Impact: DarioHealth is focusing on its core B2B2C business, and while facing revenue fluctuations in the short term, the long-term strategic intent is to enhance sustainable revenue sources.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DRIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DRIO
Wall Street analysts forecast DRIO stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 8.240
Low
11.00
Averages
13.50
High
16.00
Current: 8.240
Low
11.00
Averages
13.50
High
16.00
About DRIO
DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DarioHealth Reports Strong 2025 Financial Results
- Revenue Growth: Q4 2025 revenues reached $5.2 million, up from $5.0 million in Q3 2025, indicating a positive recovery trend despite a decline in full-year revenue to $22.4 million from $27.0 million in 2024 due to client loss.
- Margin Improvement: GAAP gross margins increased to 57% in 2025 from 49% in 2024, while Non-GAAP margins remained at 80%, demonstrating enhanced profitability in the core B2B2C business and strengthening financial stability for the future.
- Significant Expense Reduction: Q4 2025 operating expenses decreased by 28% year-over-year, from $12.4 million to $9.0 million, reflecting improved operational efficiency post-merger, which is expected to further narrow future operating losses.
- Expanded Opportunity Pipeline: As of December 31, 2025, the company’s commercial opportunity pipeline grew to $122 million based on 230 B2B2C opportunities, showcasing strong demand for DarioHealth's offerings and significant growth potential ahead.
See More
DarioHealth (DRIO) Q4 2025 Earnings Transcript
See More
DarioHealth Reports Q4: Net Loss Up 32% Amid Revenue Shift
- Financial Performance Decline: DarioHealth's Q4 non-GAAP net loss increased by 32% to $6.5 million, reflecting the financial pressures faced during the company's transition.
- Significant Revenue Drop: The company reported revenue of $5.2 million, a 31.6% year-over-year decline, although it beat expectations by $0.15 million, primarily due to the shift from one-time revenues to annual recurring revenues (ARR).
- Client Relationship Changes: A significant scope change with a large national health plan client resulted in revenue decline, as this client was not renewed at the beginning of 2025, highlighting challenges in client retention for DarioHealth.
- Strategic Transition Impact: DarioHealth is focusing on its core B2B2C business, and while facing revenue fluctuations in the short term, the long-term strategic intent is to enhance sustainable revenue sources.
See More
DarioHealth Reports 2023 Earnings Decline
- Revenue Decline: DarioHealth's revenue for 2023 was $22.35 million, down 17.3% from $27.04 million last year, indicating pressure in market competition that could affect future investor confidence.
- Earnings Per Share Shift: The company's EPS stood at $10.12, a decrease from $12.27 last year, reflecting weakened profitability that may raise shareholder concerns about the company's earnings outlook.
- Overall Profitability: DarioHealth reported a full-year profit of $61.73 million, which, while an absolute increase, did not offset the revenue decline compared to last year's $40.98 million, highlighting challenges faced by the company.
- Market Reaction Outlook: Given the dual decline in revenue and EPS, the market is expected to adopt a cautious stance towards DarioHealth's future performance, potentially impacting its stock price trajectory and investor confidence.
See More
DarioHealth Reports Strong 2025 Financial Results and Strategic Updates
- Strong Commercial Growth: DarioHealth signed 85 new agreements in 2025, with anticipated annual recurring revenue (ARR) of $12.9 million expected to convert in 2026 and 2027, establishing a solid foundation for future growth.
- Revenue and Profit Dynamics: The company reported $5.2 million in revenue for Q4 2025, down from $7.6 million in Q4 2024, yet showed sequential growth, indicating resilience during its transition phase.
- Operational Efficiency Improvement: Total operating expenses for 2025 were $49.3 million, a 31% decrease from $71 million in 2024, primarily due to post-merger integration and enhanced operational efficiencies, which are expected to further improve financial performance.
- Market Coverage Expansion: Through partnerships with Solera, Amwell, and others, DarioHealth now has access to approximately 116 million covered lives, enhancing market penetration and reducing customer acquisition costs, driving sustainable growth.
See More
DarioHealth to Release Q4 Financial Results on March 19
- Earnings Release Announcement: DarioHealth will release its financial results for the fourth quarter ended December 31, 2025, on March 19, 2026, at 8:30 a.m. Eastern Time, providing investors with insights into the company's latest financial performance and business health.
- Conference Call Details: The call will be hosted by CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda, and is expected to attract significant investor participation, enhancing transparency and engagement.
- Participation Options: Investors can join the call by dialing 1-800-717-1738 for domestic or 1-646-307-1865 for international access, or utilize the “Call me™” link for instant connection, thereby improving accessibility for all participants.
- Replay Information: A replay of the call will be available approximately three hours after its conclusion, allowing investors who could not attend live to access critical information by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).
See More
DarioHealth Reports Strong 2025 Financial Results
- Revenue Growth: Q4 2025 revenues reached $5.2 million, up from $5.0 million in Q3 2025, indicating a positive recovery trend despite a decline in full-year revenue to $22.4 million from $27.0 million in 2024 due to client loss.
- Margin Improvement: GAAP gross margins increased to 57% in 2025 from 49% in 2024, while Non-GAAP margins remained at 80%, demonstrating enhanced profitability in the core B2B2C business and strengthening financial stability for the future.
- Significant Expense Reduction: Q4 2025 operating expenses decreased by 28% year-over-year, from $12.4 million to $9.0 million, reflecting improved operational efficiency post-merger, which is expected to further narrow future operating losses.
- Expanded Opportunity Pipeline: As of December 31, 2025, the company’s commercial opportunity pipeline grew to $122 million based on 230 B2B2C opportunities, showcasing strong demand for DarioHealth's offerings and significant growth potential ahead.
See More
DarioHealth (DRIO) Q4 2025 Earnings Transcript
See More
DarioHealth Reports Q4: Net Loss Up 32% Amid Revenue Shift
- Financial Performance Decline: DarioHealth's Q4 non-GAAP net loss increased by 32% to $6.5 million, reflecting the financial pressures faced during the company's transition.
- Significant Revenue Drop: The company reported revenue of $5.2 million, a 31.6% year-over-year decline, although it beat expectations by $0.15 million, primarily due to the shift from one-time revenues to annual recurring revenues (ARR).
- Client Relationship Changes: A significant scope change with a large national health plan client resulted in revenue decline, as this client was not renewed at the beginning of 2025, highlighting challenges in client retention for DarioHealth.
- Strategic Transition Impact: DarioHealth is focusing on its core B2B2C business, and while facing revenue fluctuations in the short term, the long-term strategic intent is to enhance sustainable revenue sources.
See More
DarioHealth Reports 2023 Earnings Decline
- Revenue Decline: DarioHealth's revenue for 2023 was $22.35 million, down 17.3% from $27.04 million last year, indicating pressure in market competition that could affect future investor confidence.
- Earnings Per Share Shift: The company's EPS stood at $10.12, a decrease from $12.27 last year, reflecting weakened profitability that may raise shareholder concerns about the company's earnings outlook.
- Overall Profitability: DarioHealth reported a full-year profit of $61.73 million, which, while an absolute increase, did not offset the revenue decline compared to last year's $40.98 million, highlighting challenges faced by the company.
- Market Reaction Outlook: Given the dual decline in revenue and EPS, the market is expected to adopt a cautious stance towards DarioHealth's future performance, potentially impacting its stock price trajectory and investor confidence.
See More
DarioHealth Reports Strong 2025 Financial Results and Strategic Updates
- Strong Commercial Growth: DarioHealth signed 85 new agreements in 2025, with anticipated annual recurring revenue (ARR) of $12.9 million expected to convert in 2026 and 2027, establishing a solid foundation for future growth.
- Revenue and Profit Dynamics: The company reported $5.2 million in revenue for Q4 2025, down from $7.6 million in Q4 2024, yet showed sequential growth, indicating resilience during its transition phase.
- Operational Efficiency Improvement: Total operating expenses for 2025 were $49.3 million, a 31% decrease from $71 million in 2024, primarily due to post-merger integration and enhanced operational efficiencies, which are expected to further improve financial performance.
- Market Coverage Expansion: Through partnerships with Solera, Amwell, and others, DarioHealth now has access to approximately 116 million covered lives, enhancing market penetration and reducing customer acquisition costs, driving sustainable growth.
See More
DarioHealth to Release Q4 Financial Results on March 19
- Earnings Release Announcement: DarioHealth will release its financial results for the fourth quarter ended December 31, 2025, on March 19, 2026, at 8:30 a.m. Eastern Time, providing investors with insights into the company's latest financial performance and business health.
- Conference Call Details: The call will be hosted by CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda, and is expected to attract significant investor participation, enhancing transparency and engagement.
- Participation Options: Investors can join the call by dialing 1-800-717-1738 for domestic or 1-646-307-1865 for international access, or utilize the “Call me™” link for instant connection, thereby improving accessibility for all participants.
- Replay Information: A replay of the call will be available approximately three hours after its conclusion, allowing investors who could not attend live to access critical information by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).
See More
